|
시장보고서
상품코드
1403523
종합적 대사 패널 검사 시장 예측(-2030년) : 검사 유형, 질병, 최종 사용자 및 지역별 세계 분석Comprehensive Metabolic Panel Testing Market Forecasts to 2030 - Global Analysis By Test Type, Disease, End User and by Geography |
||||||
Stratistics MRC에 따르면, 세계 종합 대사 패널 검사 시장은 2023년 113억 2,000만 달러로 추정되며, 예측 기간 동안 11.1%의 연평균 복합 성장률(CAGR)로 성장하여 2030년에는 236억 5,000만 달러에 이를 것으로 예상됩니다. 전망됩니다.
종합적 대사 패널(CMP)이라고 불리는 진단용 혈액 검사는 사람의 대사 건강 상태를 철저하게 평가합니다. 이는 혈당, 전해질 균형 및 장기 기능과 관련된 수많은 마커를 평가합니다. 혈액 내 포도당, 전해질, 간, 신장 및 단백질 수치에 대한 검사는 일반적으로 CMP에 포함됩니다. 또한 이 패널은 간과 신장과 같은 중요한 장기의 전반적인 건강 상태에 대한 통찰력 있는 정보를 제공하여 당뇨병, 간 질환, 신장 기능 장애와 같은 질병을 식별하고 추적하는 데 도움이 됩니다.
국제당뇨병연맹(IDF)에 따르면, 전 세계적으로 5억 4,000만 명 이상의 사람들이 당뇨병을 앓고 있으며, 2045년에는 그 수가 7억 8,000만 명을 넘어설 것으로 예상됩니다.
대사성 질환의 빈도 증가
종합적 대사 패널(CMP) 검사 시장을 촉진하는 주요 요인 중 하나는 당뇨병, 비만, 비알코올성 지방간 질환과 같은 대사성 질환의 전 세계 유병률 증가입니다. 또한, 이러한 질병과 관련된 생활습관 요인 및 식습관 패턴의 유병률이 증가함에 따라 조기 발견, 중재 및 효율적인 질병 관리를 촉진하기 위해 정기적인 대사 프로파일링이 필수적입니다.
교육과 낮은 의식수준
예방적 건강관리에 대한 관심이 높아지고 있지만, 완전 대사 패널 검사의 중요성에 대한 지식의 격차는 여전히 큽니다. 이러한 검사가 제공하는 종합적인 데이터의 범위와 질병의 조기 발견에 있어 그 중요성에 대한 의료 전문가와 일반 대중의 인식 부족이 검사의 활용을 방해하고 있습니다. 이러한 한계를 극복하기 위해서는 일반 대중과 의료 전문가를 대상으로 대사성 건강 모니터링에 대한 지식과 적극적인 참여를 촉진하는 집중적인 교육 캠페인이 필요합니다.
표적치료와 개인맞춤형 의료
맞춤형 의료에 대한 관심이 높아짐에 따라 시장에는 큰 기회가 있습니다. 분자진단학 및 유전자 프로파일링이 지속적으로 발전하고 있는 가운데, 대사 패널 데이터와 개인 유전자 정보를 결합하여 치료 계획의 정확도를 높일 수 있습니다. 또한, 환자별 대사 프로파일에 적합한 표적치료제 개발이 가능해져 치료 효과 향상과 부작용 감소를 기대할 수 있습니다.
가격압박과 경쟁환경
CMP 검사 시장은 가격 압력뿐만 아니라 업계로부터도 큰 위협을 받고 있습니다. 진단 기업 간의 가격 경쟁은 치열한 경쟁으로 인해 종합 대사 패널 검사 서비스의 장기적인 생존을 위태롭게 할 수 있습니다. 또한, 검사 기관은 고객 만족도를 희생하지 않고 이 치열한 시장에서 살아남기 위해 비용 절감 전략, 부가가치 서비스 및 전략적 차별화를 활용해야 합니다.
COVID-19의 영향 :
코로나19가 시장에 미친 영향은 여러 가지가 있는데, CMP 검사를 포함한 일상적인 진단 검사가 일시적으로 감소했는데, 이는 초기에는 의료 서비스 중단, 공급망 문제, 전염병 관리에 대한 의료계의 우선순위 변화로 인해 발생했습니다. 코로나19가 환자, 특히 대사성 합병증을 가진 환자에게 미치는 영향을 판단하는 데 있어 철저한 대사 평가의 중요성은 의료 부문이 새로운 정상에 적응함에 따라 더 많이 인식되고 있습니다. 또한, POC 검사, 원격 의료 및 디지털 건강 솔루션은 모두 전염병의 결과로 빠르게 확산되어 CMP 검사 시장의 역학을 변화시켰습니다.
예측 기간 동안 당뇨병 분야가 가장 큰 비중을 차지할 것으로 예상
당뇨병은 유병률이 높은 만성 질환이기 때문에 이 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다. 당뇨병은 전 세계적으로 수백만 명이 앓고 있는 대사성 질환으로 혈당 수치가 상승하는 것이 특징입니다. 또한, 당뇨병 관리 시장은 처방약, 혈당 측정기, 인슐린 치료, 생활습관 개선 등 다양한 제품과 서비스를 제공합니다. 좌식 생활습관 및 식습관 장애와 같은 요인으로 인해 당뇨병 유병률이 증가함에 따라 질병 관리에 대한 연구 개발 및 독창적인 접근 방식에 많은 투자가 이루어지고 있습니다.
예측기간 동안 가장 높은 CAGR을 기록할 것으로 예상되는 분야는 Point of Care Centers 분야임.
시장 CAGR이 가장 높은 분야는 현장 진료 센터 분야입니다. 현장 진료 검사는 사용 편의성, 속도, 의료 서비스 제공을 단순화할 수 있는 능력으로 인해 점점 더 인기를 얻고 있습니다. 현장 검사(point-of-care testing)는 빠른 진단과 환자의 손끝이나 가까운 곳에서 실시간으로 결과를 확인할 수 있는 것이 특징입니다. 이러한 시설에서는 다양한 진단 서비스를 제공하고 몇 분 안에 결과를 얻을 수 있습니다. 이러한 서비스에는 혈액 검사, 소변 검사 및 기타 중요한 평가가 포함됩니다. 또한, 의료 서비스의 분산화, 환자 접근성 향상, 진단 시간 단축에 대한 중요성이 강조되면서 진료소 확대에 힘을 실어주고 있습니다.
가장 큰 점유율을 차지하는 지역 :
CMP 검사 시장은 북미에서 가장 큰 점유율을 차지할 것으로 예상됩니다. 만성 대사성 질환 환자 인구가 많고, 의료 인프라가 잘 갖추어져 있으며, 예방 의료에 대한 인식이 높은 것이 이 지역의 우위를 점하는 데 기여하고 있습니다. 또한, 기술 개발, 업계 선도 기업의 존재, 유리한 상환 관행 등이 북미 CMP 검사 시장의 성장을 가속하고 있습니다.
CAGR이 가장 높은 지역 :
종합적 대사 패널(CMP) 검사 시장은 아시아태평양에서 가장 높은 CAGR을 기록할 것으로 예상됩니다. 인구 증가, 건강 관리 인식 증가, 대사 이상 유병률 증가 등 여러 요인이 이 지역의 성장을 견인하고 있습니다. 아시아태평양에서 종합적 대사 패널 검사에 대한 수요가 급증하는 배경에는 의료 인프라의 개선과 첨단 진단 기술의 도입이 있습니다. 또한, 생활습관병의 유병률 증가와 조기 발견 및 조기 관리의 중요성이 높아지면서 이 지역 시장은 견고한 성장세를 보일 것으로 예상됩니다.
무료 맞춤형 서비스
이 보고서를 구독하는 고객은 다음과 같은 무료 맞춤형 옵션 중 하나를 사용할 수 있습니다.
- 기업 프로파일
- 추가 시장 기업의 종합적인 프로파일링(최대 3개사까지)
- 주요 기업의 SWOT 분석(3개사까지)
- 지역 세분화
- 고객의 관심에 따른 주요 국가별 시장 추정 및 예측, CAGR(참고: 타당성 확인에 따라 다름)
- 경쟁사 벤치마킹
- 제품 포트폴리오, 지리적 입지, 전략적 제휴를 기반으로 한 주요 기업 벤치마킹
목차
제1장 주요 요약
제2장 서문
- 개요
- 이해관계자
- 조사 범위
- 조사 방법
- 데이터 마이닝
- 데이터 분석
- 데이터 검증
- 조사 접근
- 조사 소스
- 1차 조사 소스
- 2차 조사 소스
- 전제조건
제3장 시장 동향 분석
- 성장 촉진요인
- 성장 억제요인
- 기회
- 위협
- 최종사용자 분석
- 신흥 시장
- 신형 코로나바이러스(COVID-19)의 영향
제4장 Porter의 Five Forces 분석
- 공급 기업의 교섭력
- 바이어의 교섭력
- 대체품의 위협
- 신규 진출업체의 위협
- 경쟁 기업간 경쟁 관계
제5장 세계의 종합적 대사 패널 검사 시장 : 검사 유형별
- 글루코오스
- 칼슘
- 전해질
- 나트륨
- 칼륨
- 기타 전해질
- 신장 기능 검사
- 혈중 요소 질소(BUN)
- 크레아티닌
- 간기능 검사
- 알부민
- 빌리루빈
- Alkaline Phosphatase
- Aspartate Aminotransferase (AST)
- Alanine Aminotransferase (ALT)
- 단백질
- 기타 검사 유형
제6장 세계의 종합적 대사 패널 검사 시장 : 질환별
- 당뇨병
- 신장병
- 간질환
- 기타 질환
제7장 세계의 종합적 대사 패널 검사 시장 : 최종사용자별
- POC(Point of Care) 센터
- 진단 실험실
- 병원
- 기타 최종사용자
제8장 세계의 종합적 대사 패널 검사 시장 : 지역별
- 북미
- 미국
- 캐나다
- 멕시코
- 유럽
- 독일
- 영국
- 이탈리아
- 프랑스
- 스페인
- 기타 유럽
- 아시아태평양
- 일본
- 중국
- 인도
- 호주
- 뉴질랜드
- 한국
- 기타 아시아태평양
- 남미
- 아르헨티나
- 브라질
- 칠레
- 기타 남미
- 중동 및 아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 카타르
- 남아프리카공화국
- 기타 중동 및 아프리카
제9장 주요 발전
- 계약/파트너십/협업/합작투자(JV)
- 인수 및 합병
- 신제품 발매
- 사업 확대
- 기타 주요 전략
제10장 기업 개요
- Charles River Laboratories Inc.
- Genoptix Inc.
- Baptist Health Medical Group
- ARUP Laboratories
- Scion Lab Services LLC
- NeoGenomics Laboratories, Inc.
- Abbott Laboratories
- Unipath
- Siemens HealthCare GmbH
- Nova Medical
- CENTOGENE N.V.
- Quest Diagnostics Incorporated
- Cleveland HeartLab, Inc.
- Sonic HealthCare
- TCG Corp.
- SYNLAB International GmbH
LSH 24.01.19
According to Stratistics MRC, the Global Comprehensive Metabolic Panel Testing Market is accounted for $11.32 billion in 2023 and is expected to reach $23.65 billion by 2030 growing at a CAGR of 11.1% during the forecast period. A diagnostic blood test called a Comprehensive Metabolic Panel (CMP) offers a thorough assessment of a person's metabolic health. It assesses a number of markers linked to blood sugar, electrolyte balance, and organ function. Tests for glucose, electrolytes, and liver, kidney, and protein levels in the blood are commonly included in a CMP. Moreover, this panel helps identify and track diseases like diabetes, liver disease, and kidney dysfunction by providing insightful information about the general health of important organs like the liver and kidneys.
According to International Diabetes Federation (IDF), over 540 million people are suffering from diabetes worldwide, and by 2045 the numbers are expected to cross 780 million marks.
Market Dynamics:
Driver:
Increased frequency of metabolic illnesses
One major factor propelling the market for Comprehensive Metabolic Panel (CMP) testing is the rising prevalence of metabolic disorders worldwide, such as diabetes, obesity, and non-alcoholic fatty liver disease. Additionally, regular metabolic profiling is imperative to facilitate early detection, intervention, and efficient disease management, given the increasing prevalence of lifestyle factors and dietary patterns associated with these conditions.
Restraint:
Low level of education and awareness
Even with the growing focus on preventive healthcare, there is still a significant knowledge gap about the significance of full metabolic panel testing. The lack of awareness among healthcare professionals and the general public regarding the comprehensive range of data these tests offer and their significance in the early identification of illnesses impedes their use. Furthermore, in order to overcome this limitation, focused education campaigns that foster knowledge and proactive participation in metabolic health monitoring are required, aimed at both the general public and healthcare professionals.
Opportunity:
Targeted therapies and personalized medicine
There is a big chance for the market because of the growing emphasis on personalized medicine. The precision of treatment plans can be improved by combining metabolic panel data with individual genetic information as molecular diagnostics and genetic profiling continue to advance. Moreover, this makes it possible to develop targeted therapies that are suited to each patient's particular metabolic profile, enhancing treatment effectiveness and reducing side effects.
Threat:
Pricing pressure and the competitive environment
The CMP testing market is significantly threatened by the industry as well as pricing pressures. A pricing war amongst diagnostic companies could jeopardize the long-term viability of comprehensive metabolic panel testing services due to intense competition. Additionally, laboratories must use cost-cutting strategies, value-added services, and strategic differentiation to survive in this cutthroat market without sacrificing customer satisfaction.
COVID-19 Impact:
There are several ways in which the COVID-19 pandemic has affected the market. A brief drop in routine diagnostic testing, including CMP tests, was initially caused by disruptions in healthcare services, issues with the supply chain, and a change in healthcare priorities toward managing the pandemic. The significance of thorough metabolic assessments in determining the effects of COVID-19 on patients, particularly those with metabolic complications, was acknowledged more as the healthcare sector adjusted to the new normal. Furthermore, point-of-care testing, telemedicine, and digital health solutions have all seen rapid adoption as a result of the pandemic, which has changed the dynamics of the CMP testing market.
The Diabetes segment is expected to be the largest during the forecast period
Due to the fact that diabetes is a chronic condition with a high prevalence, it is expected to hold the largest share of the market. Diabetes is a metabolic disease that affects millions of people worldwide and is typified by elevated blood glucose levels. Moreover, a broad range of goods and services are available in the diabetes management market, such as prescription drugs, glucose monitors, insulin treatments, and lifestyle modifications. Significant investments have been made in research, development, and creative approaches to disease management as a result of the rising prevalence of diabetes, which is fueled by factors like sedentary lifestyles and poor dietary habits.
The Point of care Centers segment is expected to have the highest CAGR during the forecast period
The market's highest CAGR is being seen in the point-of-care centers segment. Point-of-care testing has become increasingly popular because of its ease of use, speed, and capacity to simplify the delivery of healthcare. It is typified by quick diagnostics and real-time results at or close to the patient. These facilities provide a broad range of diagnostic services, with results available in a matter of minutes. These services include blood tests, urinalysis, and other crucial assessments. Additionally, point-of-care center expansion has been driven by the growing emphasis on decentralizing healthcare services, increasing patient accessibility, and shortening diagnosis turnaround times.
Region with largest share:
The market for CMP testing is expected to have the largest share in the North American region. A large patient population with chronic metabolic conditions, a well-established healthcare infrastructure, and a high level of awareness regarding preventive healthcare are some of the factors contributing to the region's dominance. Furthermore, technology developments, the existence of major industry players, and advantageous reimbursement practices have all aided in the expansion of the CMP testing market in North America.
Region with highest CAGR:
The comprehensive metabolic panel (CMP) testing market is expected to grow at the highest CAGR in the Asia-Pacific region. A number of factors are driving the region's growth, such as a quickly growing population, growing healthcare awareness, and an increase in the prevalence of metabolic disorders. The Asia-Pacific region's burgeoning need for comprehensive metabolic panel testing is partly due to improved healthcare infrastructure and the uptake of cutting-edge diagnostic technologies. Moreover, the market in this region is expected to grow at a robust rate due to the increasing prevalence of lifestyle-related diseases and the growing emphasis on early detection and management.
Key players in the market:
Some of the key players in Comprehensive Metabolic Panel Testing market include Charles River Laboratories Inc., Genoptix Inc., Baptist Health Medical Group, ARUP Laboratories, Scion Lab Services LLC, NeoGenomics Laboratories, Inc., Abbott Laboratories, Unipath, Siemens Healthcare GmbH, Nova Medical, CENTOGENE N.V., Quest Diagnostics Incorporated, Cleveland HeartLab, Inc., Sonic Healthcare, TCG Corp. and SYNLAB International GmbH.
Key Developments:
In December 2023, Charles River Laboratories International, Inc. announced an important milestone in their strategic collaboration to manufacture CASGEVY™. CASGEVY is approved in some countries for certain eligible patients. The news follows Charles River's Memphis center of excellence passing back-to-back audits from both the U.S. Food and Drug Administration and the Health Products Regulatory Authority, on behalf of the European Medicines Agency.
In December 2023, Baptist Health Baptist Hospital launched the Inspiration Hall, powered by national leader in hospice and palliative care services, VITAS Healthcare. Located on the first floor near the hospital's imaging center waiting room, the Inspiration Hall is an immersive experience where patients, visitors and hospital team members can submit, read or watch messages of comfort and support that will inspire others in their health journey.
In December 2023, A partnership between ARUP Laboratories and Medicover has made a new companion diagnostic, and thereby a new gene therapy, more accessible to patients in the European Union. ARUP Laboratories, in close collaboration with BioMarin Pharmaceutical Inc., developed AAV5 DetectCDx™, a companion diagnostic that aids in the selection of adult patients with severe hemophilia A who are eligible for treatment with ROCTAVIAN™, a new gene therapy developed by BioMarin.
Test Types Covered:
- Glucose
- Calcium
- Electrolytes
- Kidney Function Tests
- Liver Function Tests
- Proteins
- Other Test Types
Diseases Covered:
- Diabetes
- Kidney Disease
- Liver Disease
- Other Diseases
End Users Covered:
- Point of Care Centers
- Diagnostic Laboratories
- Hospitals
- Other End Users
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Comprehensive Metabolic Panel Testing Market, By Test Type
- 5.1 Introduction
- 5.2 Glucose
- 5.3 Calcium
- 5.4 Electrolytes
- 5.4.1 Sodium
- 5.4.2 Potassium
- 5.4.3 Other Electrolytes
- 5.5 Kidney Function Tests
- 5.5.1 Blood Urea Nitrogen (BUN)
- 5.5.2 Creatinine
- 5.6 Liver Function Tests
- 5.6.1 Albumin
- 5.6.2 Bilirubin
- 5.6.3 Alkaline Phosphatase
- 5.6.4 Aspartate Aminotransferase (AST)
- 5.6.5 Alanine Aminotransferase (ALT)
- 5.7 Proteins
- 5.8 Other Test Types
6 Global Comprehensive Metabolic Panel Testing Market, By Disease
- 6.1 Introduction
- 6.2 Diabetes
- 6.3 Kidney Disease
- 6.4 Liver Disease
- 6.5 Other Diseases
7 Global Comprehensive Metabolic Panel Testing Market, By End User
- 7.1 Introduction
- 7.2 Point of Care Centers
- 7.3 Diagnostic Laboratories
- 7.4 Hospitals
- 7.5 Other End Users
8 Global Comprehensive Metabolic Panel Testing Market, By Geography
- 8.1 Introduction
- 8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
- 8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
- 8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa
9 Key Developments
- 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 9.2 Acquisitions & Mergers
- 9.3 New Product Launch
- 9.4 Expansions
- 9.5 Other Key Strategies
10 Company Profiling
- 10.1 Charles River Laboratories Inc.
- 10.2 Genoptix Inc.
- 10.3 Baptist Health Medical Group
- 10.4 ARUP Laboratories
- 10.5 Scion Lab Services LLC
- 10.6 NeoGenomics Laboratories, Inc.
- 10.7 Abbott Laboratories
- 10.8 Unipath
- 10.9 Siemens HealthCare GmbH
- 10.10 Nova Medical
- 10.11 CENTOGENE N.V.
- 10.12 Quest Diagnostics Incorporated
- 10.13 Cleveland HeartLab, Inc.
- 10.14 Sonic HealthCare
- 10.15 TCG Corp.
- 10.16 SYNLAB International GmbH
- 추가 시장 기업의 종합적인 프로파일링(최대 3개사까지)
- 주요 기업의 SWOT 분석(3개사까지)
- 고객의 관심에 따른 주요 국가별 시장 추정 및 예측, CAGR(참고: 타당성 확인에 따라 다름)
- 제품 포트폴리오, 지리적 입지, 전략적 제휴를 기반으로 한 주요 기업 벤치마킹
- 데이터 마이닝
- 데이터 분석
- 데이터 검증
- 조사 접근
- 1차 조사 소스
- 2차 조사 소스
- 전제조건
- 나트륨
- 칼륨
- 기타 전해질
- 혈중 요소 질소(BUN)
- 크레아티닌
- 알부민
- 빌리루빈
- Alkaline Phosphatase
- Aspartate Aminotransferase (AST)
- Alanine Aminotransferase (ALT)
- 미국
- 캐나다
- 멕시코
- 독일
- 영국
- 이탈리아
- 프랑스
- 스페인
- 기타 유럽
- 일본
- 중국
- 인도
- 호주
- 뉴질랜드
- 한국
- 기타 아시아태평양
- 아르헨티나
- 브라질
- 칠레
- 기타 남미
- 사우디아라비아
- 아랍에미리트(UAE)
- 카타르
- 남아프리카공화국
- 기타 중동 및 아프리카
According to Stratistics MRC, the Global Comprehensive Metabolic Panel Testing Market is accounted for $11.32 billion in 2023 and is expected to reach $23.65 billion by 2030 growing at a CAGR of 11.1% during the forecast period. A diagnostic blood test called a Comprehensive Metabolic Panel (CMP) offers a thorough assessment of a person's metabolic health. It assesses a number of markers linked to blood sugar, electrolyte balance, and organ function. Tests for glucose, electrolytes, and liver, kidney, and protein levels in the blood are commonly included in a CMP. Moreover, this panel helps identify and track diseases like diabetes, liver disease, and kidney dysfunction by providing insightful information about the general health of important organs like the liver and kidneys.
According to International Diabetes Federation (IDF), over 540 million people are suffering from diabetes worldwide, and by 2045 the numbers are expected to cross 780 million marks.
Market Dynamics:
Driver:
Increased frequency of metabolic illnesses
One major factor propelling the market for Comprehensive Metabolic Panel (CMP) testing is the rising prevalence of metabolic disorders worldwide, such as diabetes, obesity, and non-alcoholic fatty liver disease. Additionally, regular metabolic profiling is imperative to facilitate early detection, intervention, and efficient disease management, given the increasing prevalence of lifestyle factors and dietary patterns associated with these conditions.
Restraint:
Low level of education and awareness
Even with the growing focus on preventive healthcare, there is still a significant knowledge gap about the significance of full metabolic panel testing. The lack of awareness among healthcare professionals and the general public regarding the comprehensive range of data these tests offer and their significance in the early identification of illnesses impedes their use. Furthermore, in order to overcome this limitation, focused education campaigns that foster knowledge and proactive participation in metabolic health monitoring are required, aimed at both the general public and healthcare professionals.
Opportunity:
Targeted therapies and personalized medicine
There is a big chance for the market because of the growing emphasis on personalized medicine. The precision of treatment plans can be improved by combining metabolic panel data with individual genetic information as molecular diagnostics and genetic profiling continue to advance. Moreover, this makes it possible to develop targeted therapies that are suited to each patient's particular metabolic profile, enhancing treatment effectiveness and reducing side effects.
Threat:
Pricing pressure and the competitive environment
The CMP testing market is significantly threatened by the industry as well as pricing pressures. A pricing war amongst diagnostic companies could jeopardize the long-term viability of comprehensive metabolic panel testing services due to intense competition. Additionally, laboratories must use cost-cutting strategies, value-added services, and strategic differentiation to survive in this cutthroat market without sacrificing customer satisfaction.
COVID-19 Impact:
There are several ways in which the COVID-19 pandemic has affected the market. A brief drop in routine diagnostic testing, including CMP tests, was initially caused by disruptions in healthcare services, issues with the supply chain, and a change in healthcare priorities toward managing the pandemic. The significance of thorough metabolic assessments in determining the effects of COVID-19 on patients, particularly those with metabolic complications, was acknowledged more as the healthcare sector adjusted to the new normal. Furthermore, point-of-care testing, telemedicine, and digital health solutions have all seen rapid adoption as a result of the pandemic, which has changed the dynamics of the CMP testing market.
The Diabetes segment is expected to be the largest during the forecast period
Due to the fact that diabetes is a chronic condition with a high prevalence, it is expected to hold the largest share of the market. Diabetes is a metabolic disease that affects millions of people worldwide and is typified by elevated blood glucose levels. Moreover, a broad range of goods and services are available in the diabetes management market, such as prescription drugs, glucose monitors, insulin treatments, and lifestyle modifications. Significant investments have been made in research, development, and creative approaches to disease management as a result of the rising prevalence of diabetes, which is fueled by factors like sedentary lifestyles and poor dietary habits.
The Point of care Centers segment is expected to have the highest CAGR during the forecast period
The market's highest CAGR is being seen in the point-of-care centers segment. Point-of-care testing has become increasingly popular because of its ease of use, speed, and capacity to simplify the delivery of healthcare. It is typified by quick diagnostics and real-time results at or close to the patient. These facilities provide a broad range of diagnostic services, with results available in a matter of minutes. These services include blood tests, urinalysis, and other crucial assessments. Additionally, point-of-care center expansion has been driven by the growing emphasis on decentralizing healthcare services, increasing patient accessibility, and shortening diagnosis turnaround times.
Region with largest share:
The market for CMP testing is expected to have the largest share in the North American region. A large patient population with chronic metabolic conditions, a well-established healthcare infrastructure, and a high level of awareness regarding preventive healthcare are some of the factors contributing to the region's dominance. Furthermore, technology developments, the existence of major industry players, and advantageous reimbursement practices have all aided in the expansion of the CMP testing market in North America.
Region with highest CAGR:
The comprehensive metabolic panel (CMP) testing market is expected to grow at the highest CAGR in the Asia-Pacific region. A number of factors are driving the region's growth, such as a quickly growing population, growing healthcare awareness, and an increase in the prevalence of metabolic disorders. The Asia-Pacific region's burgeoning need for comprehensive metabolic panel testing is partly due to improved healthcare infrastructure and the uptake of cutting-edge diagnostic technologies. Moreover, the market in this region is expected to grow at a robust rate due to the increasing prevalence of lifestyle-related diseases and the growing emphasis on early detection and management.
Key players in the market:
Some of the key players in Comprehensive Metabolic Panel Testing market include Charles River Laboratories Inc., Genoptix Inc., Baptist Health Medical Group, ARUP Laboratories, Scion Lab Services LLC, NeoGenomics Laboratories, Inc., Abbott Laboratories, Unipath, Siemens Healthcare GmbH, Nova Medical, CENTOGENE N.V., Quest Diagnostics Incorporated, Cleveland HeartLab, Inc., Sonic Healthcare, TCG Corp. and SYNLAB International GmbH.
Key Developments:
In December 2023, Charles River Laboratories International, Inc. announced an important milestone in their strategic collaboration to manufacture CASGEVY™. CASGEVY is approved in some countries for certain eligible patients. The news follows Charles River's Memphis center of excellence passing back-to-back audits from both the U.S. Food and Drug Administration and the Health Products Regulatory Authority, on behalf of the European Medicines Agency.
In December 2023, Baptist Health Baptist Hospital launched the Inspiration Hall, powered by national leader in hospice and palliative care services, VITAS Healthcare. Located on the first floor near the hospital's imaging center waiting room, the Inspiration Hall is an immersive experience where patients, visitors and hospital team members can submit, read or watch messages of comfort and support that will inspire others in their health journey.
In December 2023, A partnership between ARUP Laboratories and Medicover has made a new companion diagnostic, and thereby a new gene therapy, more accessible to patients in the European Union. ARUP Laboratories, in close collaboration with BioMarin Pharmaceutical Inc., developed AAV5 DetectCDx™, a companion diagnostic that aids in the selection of adult patients with severe hemophilia A who are eligible for treatment with ROCTAVIAN™, a new gene therapy developed by BioMarin.
Test Types Covered:
- Glucose
- Calcium
- Electrolytes
- Kidney Function Tests
- Liver Function Tests
- Proteins
- Other Test Types
Diseases Covered:
- Diabetes
- Kidney Disease
- Liver Disease
- Other Diseases
End Users Covered:
- Point of Care Centers
- Diagnostic Laboratories
- Hospitals
- Other End Users
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Comprehensive Metabolic Panel Testing Market, By Test Type
- 5.1 Introduction
- 5.2 Glucose
- 5.3 Calcium
- 5.4 Electrolytes
- 5.4.1 Sodium
- 5.4.2 Potassium
- 5.4.3 Other Electrolytes
- 5.5 Kidney Function Tests
- 5.5.1 Blood Urea Nitrogen (BUN)
- 5.5.2 Creatinine
- 5.6 Liver Function Tests
- 5.6.1 Albumin
- 5.6.2 Bilirubin
- 5.6.3 Alkaline Phosphatase
- 5.6.4 Aspartate Aminotransferase (AST)
- 5.6.5 Alanine Aminotransferase (ALT)
- 5.7 Proteins
- 5.8 Other Test Types
6 Global Comprehensive Metabolic Panel Testing Market, By Disease
- 6.1 Introduction
- 6.2 Diabetes
- 6.3 Kidney Disease
- 6.4 Liver Disease
- 6.5 Other Diseases
7 Global Comprehensive Metabolic Panel Testing Market, By End User
- 7.1 Introduction
- 7.2 Point of Care Centers
- 7.3 Diagnostic Laboratories
- 7.4 Hospitals
- 7.5 Other End Users
8 Global Comprehensive Metabolic Panel Testing Market, By Geography
- 8.1 Introduction
- 8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
- 8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
- 8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa
9 Key Developments
- 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 9.2 Acquisitions & Mergers
- 9.3 New Product Launch
- 9.4 Expansions
- 9.5 Other Key Strategies
10 Company Profiling
- 10.1 Charles River Laboratories Inc.
- 10.2 Genoptix Inc.
- 10.3 Baptist Health Medical Group
- 10.4 ARUP Laboratories
- 10.5 Scion Lab Services LLC
- 10.6 NeoGenomics Laboratories, Inc.
- 10.7 Abbott Laboratories
- 10.8 Unipath
- 10.9 Siemens HealthCare GmbH
- 10.10 Nova Medical
- 10.11 CENTOGENE N.V.
- 10.12 Quest Diagnostics Incorporated
- 10.13 Cleveland HeartLab, Inc.
- 10.14 Sonic HealthCare
- 10.15 TCG Corp.
- 10.16 SYNLAB International GmbH
